Literature DB >> 35352177

[Multimodal rheumatological complex treatment : A current inventory].

Philipp Klemm1, Ulf Müller-Ladner2, Uwe Lange2.   

Abstract

Current data demonstrate for the first time the effects of multimodal rheumatological complex treatment (MRCT). As designed in 2005, MRCT successfully treats the pain and functional limitations caused by rheumatic and degenerative diseases and reduces disease activity. In addition to the presentation of the current evidence, the article provides concrete recommendations for implementation as well as assistance in the examination by the medical service.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Degenerative disease; Disease activity; Effect; Pain; Physical therapy

Mesh：

Year:  2022        PMID： 35352177     DOI： 10.1007/s00393-022-01181-w

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


  26 in total

1.  Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Authors:  Katerina Chatzidionysiou; Elisabeth Lie; Evgeny Nasonov; Galina Lukina; Merete Lund Hetland; Ulrik Tarp; Cem Gabay; Piet L C M van Riel; Dan C Nordström; Juan Gomez-Reino; Karel Pavelka; Matija Tomsic; Tore K Kvien; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2011-05-12       Impact factor: 19.103

2.  [Non-drug treatment of rheumatoid arthritis : An analysis of claims data and a survey of insured persons (Project PROCLAIR)].

Authors:  H Jacobs; J Callhoff; F Hoffmann; A Zink; K Albrecht
Journal:  Z Rheumatol       Date:  2019-03       Impact factor: 1.372

Review 3.  [Reality of care for musculoskeletal diseases at the population level : Results of the PROCLAIR collaborative project. German version].

Authors:  J Callhoff; K Albrecht; F Hoffmann; D Poddubnyy; K-P Günther; A Zink
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

4.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

5.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

Review 6.  [S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].

Authors:  C Fiehn; J Holle; C Iking-Konert; J Leipe; C Weseloh; M Frerix; R Alten; F Behrens; C Baerwald; J Braun; H Burkhardt; G Burmester; J Detert; M Gaubitz; A Gause; E Gromnica-Ihle; H Kellner; A Krause; J Kuipers; H-M Lorenz; U Müller-Ladner; M Nothacker; H Nüsslein; A Rubbert-Roth; M Schneider; H Schulze-Koops; S Seitz; H Sitter; C Specker; H-P Tony; S Wassenberg; J Wollenhaupt; K Krüger
Journal:  Z Rheumatol       Date:  2018-08       Impact factor: 1.372

7.  Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis.

Authors:  Natalia Bello; Adrien Etcheto; Caroline Béal; Maxime Dougados; Anna Moltó
Journal:  Arthritis Res Ther       Date:  2016-02-09       Impact factor: 5.156

Review 8.  Targeting inflammatory pathways in axial spondyloarthritis.

Authors:  Daniel E Furst; James S Louie
Journal:  Arthritis Res Ther       Date:  2019-06-04       Impact factor: 5.156

9.  Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.

Authors:  Daniel Aletaha; Jen-Fue Maa; Su Chen; Sung-Hwan Park; Dave Nicholls; Stefan Florentinus; Daniel Furtner; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2019-08-21       Impact factor: 19.103

10.  Measurement of patient outcome in arthritis.

Authors:  J F Fries; P Spitz; R G Kraines; H R Holman
Journal:  Arthritis Rheum       Date:  1980-02
View more
  1 in total

1.  Alliance chain-based simulation on a new clinical research data pricing model.

Authors:  Jing Li; Dejian Wang; Guoqiang Qi; Zheming Li; Jian Huang; Zhu Zhu; Chen Shen; Bo Lin; Kexiong Dong; Baolong Zhao; Qiang Shu; Jianwei Yin; Gang Yu
Journal:  Ann Transl Med       Date:  2022-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.